{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:20:57Z","timestamp":1770960057176,"version":"3.50.1"},"reference-count":39,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Shanghai Sixth People\u2019s Hospital","award":["Lygl202407"],"award-info":[{"award-number":["Lygl202407"]}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["2020YJZX0205"],"award-info":[{"award-number":["2020YJZX0205"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Sage Open Medical Case Reports"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>Carfilzomib is a second-generation irreversible proteasome inhibitors commonly used in the treatment of relapsed or refractory multiple myeloma. However, cardiac toxicity (heart failure, hypertension, coronary heart disease, etc.) has become the main factor leading to its reduction or withdrawal. We report a case of a 55-year-old female patient with multiple myeloma who developed sinus bradycardia following the administration of carfilzomib, along with a review of the relevant literature. The correlation between carfilzomib and cardiotoxicity was assessed by reviewing the medical history, applying the adverse drug reaction correlation evaluation, and using the Naranjo assessment scale. The clinical manifestations included chest tightness, shortness of breath, and abnormal electrocardiogram monitoring. The condition was effectively managed following treatment with a combination of trimetazidine and salbutamol. We conducted a literature review of 27 published cases of proteasome inhibitor-induced cardiac toxicity. In the 27 published cases, 12 cases were caused by carfilzomib (44.4%). To our knowledge, this is the first reported case of carfilzomib-associated sinus bradycardia, expanding the spectrum of proteasome inhibitors-related cardiotoxicity. This provides inspiration for suspected patients to stop using carfilzomib early and symptomatic treatment can effectively reduce mortality and improve prognosis.<\/jats:p>","DOI":"10.1177\/2050313x251411140","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:10:40Z","timestamp":1769559040000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Carfilzomib-induced sinus bradycardia: A case report and literature review"],"prefix":"10.1177","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7713-4339","authenticated-orcid":false,"given":"Xincai","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Shanghai Sixth People\u2019s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, China"},{"name":"Shanghai Shenkang Hospital Management Research Institute, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Demei","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shanghai Sixth People\u2019s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shanghai Sixth People\u2019s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shanghai Sixth People\u2019s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sida","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Sixth People\u2019s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shanghai Sixth People\u2019s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunkang","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Sixth People\u2019s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianping","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shanghai Sixth People\u2019s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0003"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-403733"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-017-9707-8"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.740796"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0755"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-204383"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.37616\/2212-5043.1311"},{"key":"e_1_3_3_10_2","first-page":"87","article-title":"Incidence and management of adverse events in patients with relapsed and\/or refractory multiple myeloma receiving single-agent carfilzomib","volume":"6","author":"Harvey D.","year":"2014","unstructured":"Harvey D. Incidence and management of adverse events in patients with relapsed and\/or refractory multiple myeloma receiving single-agent carfilzomib. Clin Pharmacol 2014; 6: 87\u201396.","journal-title":"Clin Pharmacol"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16889"},{"key":"e_1_3_3_12_2","first-page":"577","article-title":"Chinese guideline principles for clinical application of carfilzomib in multiple myeloma (2024 version)","volume":"33","author":"Multiple Myeloma Expert Committee of Chinese Society of Clinical Oncology (CSCO)","year":"2024","unstructured":"Multiple Myeloma Expert Committee of Chinese Society of Clinical Oncology (CSCO). Chinese guideline principles for clinical application of carfilzomib in multiple myeloma (2024 version). J Leukemia Lymphoma 2024; 33: 577\u2013586.","journal-title":"J Leukemia Lymphoma"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30578-8"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000340050"},{"issue":"1","key":"e_1_3_3_17_2","first-page":"17","article-title":"Carfilzomib induced cardiotoxicity in a multiple myeloma patient","volume":"6","author":"M\u00e9ndez-Toro A","year":"2020","unstructured":"M\u00e9ndez-Toro A, D\u00edaz-Brochero C, Acosta-Guti\u00e9rrez E. Carfilzomib induced cardiotoxicity in a multiple myeloma patient. Cardiooncology 2020; 6(1): 17.","journal-title":"Cardiooncology"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-010-0586-9"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12012-011-9146-7"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2026-z"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.2174\/1871529X19666181205100705"},{"issue":"6","key":"e_1_3_3_22_2","first-page":"28982","article-title":"Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy","volume":"5","author":"Meseeha MG","year":"2015","unstructured":"Meseeha MG, Kolade VO, Attia MN, et al. Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy. J Community Hosp Int Med Perspect 2015; 5(6): 28982.","journal-title":"J Community Hosp Int Med Perspect"},{"issue":"6","key":"e_1_3_3_23_2","first-page":"12263","article-title":"Bortezomib-induced multiple organ failure: report of two cases and review of literature","volume":"9","author":"Feng Y","year":"2016","unstructured":"Feng Y, Yang S, Gao L, et al. Bortezomib-induced multiple organ failure: report of two cases and review of literature. Int J Clin Exp Med 2016; 9(6): 12263\u201312268.","journal-title":"Int J Clin Exp Med"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12039"},{"key":"e_1_3_3_25_2","first-page":"1","article-title":"The first autopsy case of fatal acute cardiac failure after administration of carfilzomib in a patient with multiple myeloma","volume":"2019","author":"Takakuwa T","year":"2019","unstructured":"Takakuwa T, Otomaru I, Araki T, et al. The first autopsy case of fatal acute cardiac failure after administration of carfilzomib in a patient with multiple myeloma. Case Rep Hematol 2019; 2019: 1\u20135.","journal-title":"Case Rep Hematol"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3456287"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1080\/10245332.2017.1328165"},{"issue":"4","key":"e_1_3_3_28_2","article-title":"Bortezomib induced reversible left ventricular systolic dysfunction: a case report and review of literature","volume":"6","author":"Chakraborty R","year":"2013","unstructured":"Chakraborty R, Mukkamalla SKR, Calderon N. Bortezomib induced reversible left ventricular systolic dysfunction: a case report and review of literature. Br J Med Pract 2013; 6(4): a631.","journal-title":"Br J Med Pract"},{"key":"e_1_3_3_29_2","first-page":"1","article-title":"Carfilzomib-induced pulmonary hypertension with associated right ventricular dysfunction: a case report","volume":"9","author":"McGregor PC","year":"2021","unstructured":"McGregor PC, Boosalis V, Aragam J. Carfilzomib-induced pulmonary hypertension with associated right ventricular dysfunction: a case report. SAGE Open Med Case Rep 2021; 9: 1\u20134.","journal-title":"SAGE Open Med Case Rep"},{"issue":"3","key":"e_1_3_3_30_2","article-title":"Cyclophosphamide, bortezomib, and dexamethasone and severe systolic heart failure: a case report","volume":"16","author":"Pandey S","year":"2024","unstructured":"Pandey S, Tan EFS, Bellamkonda A, et al. Cyclophosphamide, bortezomib, and dexamethasone and severe systolic heart failure: a case report. Cureus 2024; 16(3): e56966.","journal-title":"Cureus"},{"issue":"1","key":"e_1_3_3_31_2","article-title":"Carfilzomib-induced tumor lysis syndrome and biventricular heart failure in a patient with multiple myeloma","volume":"15","author":"Azad F","year":"2023","unstructured":"Azad F, Moyer R, Miranda CJ, et al. Carfilzomib-induced tumor lysis syndrome and biventricular heart failure in a patient with multiple myeloma. Cureus 2023; 15(1): e33538.","journal-title":"Cureus"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1159\/000520382"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1159\/000502538"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-6-129"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.2194-18"},{"key":"e_1_3_3_36_2","first-page":"1","article-title":"Carfilzomib induced cardiotoxicity in a multiple myeloma patient","volume":"7","author":"Toro AM","year":"2020","unstructured":"Toro AM, Diaz-Brochero C, Acosta-Gutierrez E. Carfilzomib induced cardiotoxicity in a multiple myeloma patient. Cardiooncology 2020; 7: 1\u20138.","journal-title":"Cardiooncology"},{"issue":"5","key":"e_1_3_3_37_2","first-page":"172","article-title":"Carfilzomib-induced pulmonary hypertension in a patient with multiple myeloma","volume":"30","author":"Uruno K","year":"2024","unstructured":"Uruno K, Iwano H, Hayashi T, et al. Carfilzomib-induced pulmonary hypertension in a patient with multiple myeloma. J Cardiol Cases 2024; 30(5): 172\u2013175.","journal-title":"J Cardiol Cases"},{"issue":"5","key":"e_1_3_3_38_2","first-page":"197","article-title":"Coronary spastic angina in a multiple myeloma patient treated with bortezomib, lenalidomide, and dexamethasone","volume":"21","author":"Yasui T","year":"2020","unstructured":"Yasui T, Shioyama W, Oboshi M, et al. Coronary spastic angina in a multiple myeloma patient treated with bortezomib, lenalidomide, and dexamethasone. J Cardiol Cases 2020; 21(5): 197\u2013199.","journal-title":"J Cardiol Cases"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022247"},{"issue":"5","key":"e_1_3_3_40_2","article-title":"Predictive value of ECG ischemic pattern changes for the10-year occurrence of ischemic heart disease","volume":"30","author":"Sara SS","year":"2025","unstructured":"Sara SS, Malihehsadat A, Eisa N, et al. Predictive value of ECG ischemic pattern changes for the10-year occurrence of ischemic heart disease. Ann Noninvas Electro 2025; 30(5): e70111.","journal-title":"Ann Noninvas Electro"}],"container-title":["Sage Open Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X251411140","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2050313X251411140","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X251411140","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T03:46:18Z","timestamp":1769744778000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2050313X251411140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":39,"alternative-id":["10.1177\/2050313X251411140"],"URL":"https:\/\/doi.org\/10.1177\/2050313x251411140","relation":{},"ISSN":["2050-313X","2050-313X"],"issn-type":[{"value":"2050-313X","type":"print"},{"value":"2050-313X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"2050313X251411140"}}